Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Molecular Pathways Mediating Immunosuppression in Response to Prolonged Intensive Physical Training, Low-Energy Availability, and Intensive Weight Loss.

Sarin HV, Gudelj I, Honkanen J, Ihalainen JK, Vuorela A, Lee JH, Jin Z, Terwilliger JD, Isola V, Ahtiainen JP, Häkkinen K, Jurić J, Lauc G, Kristiansson K, Hulmi JJ, Perola M.

Front Immunol. 2019 May 3;10:907. doi: 10.3389/fimmu.2019.00907. eCollection 2019.

2.

ODM-204, a Novel Dual Inhibitor of CYP17A1 and Androgen Receptor: Early Results from Phase I Dose Escalation in Men with Castration-resistant Prostate Cancer.

Peltola KJ, Bono P, Jones RH, Vjaters E, Nykänen P, Vuorela A, Oksala R, Pohjanjousi P, Mustonen MVJ, Fizazi K, Massard C.

Eur Urol Focus. 2018 Sep 4. pii: S2405-4569(18)30241-4. doi: 10.1016/j.euf.2018.08.022. [Epub ahead of print]

3.

Pharmacokinetics, Antitumor Activity, and Safety of ODM-201 in Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: An Open-label Phase 1 Study.

Massard C, Penttinen HM, Vjaters E, Bono P, Lietuvietis V, Tammela TL, Vuorela A, Nykänen P, Pohjanjousi P, Snapir A, Fizazi K.

Eur Urol. 2016 May;69(5):834-40. doi: 10.1016/j.eururo.2015.09.046. Epub 2015 Oct 17.

4.

Autoantibodies against ganglioside GM3 are associated with narcolepsy-cataplexy developing after Pandemrix vaccination against 2009 pandemic H1N1 type influenza virus.

Saariaho AH, Vuorela A, Freitag TL, Pizza F, Plazzi G, Partinen M, Vaarala O, Meri S.

J Autoimmun. 2015 Sep;63:68-75. doi: 10.1016/j.jaut.2015.07.006. Epub 2015 Jul 27.

PMID:
26227560
5.

Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2.

Ahmed SS, Volkmuth W, Duca J, Corti L, Pallaoro M, Pezzicoli A, Karle A, Rigat F, Rappuoli R, Narasimhan V, Julkunen I, Vuorela A, Vaarala O, Nohynek H, Pasini FL, Montomoli E, Trombetta C, Adams CM, Rothbard J, Steinman L.

Sci Transl Med. 2015 Jul 1;7(294):294ra105. doi: 10.1126/scitranslmed.aab2354.

PMID:
26136476
6.

Antigenic differences between AS03 adjuvanted influenza A (H1N1) pandemic vaccines: implications for pandemrix-associated narcolepsy risk.

Vaarala O, Vuorela A, Partinen M, Baumann M, Freitag TL, Meri S, Saavalainen P, Jauhiainen M, Soliymani R, Kirjavainen T, Olsen P, Saarenpää-Heikkilä O, Rouvinen J, Roivainen M, Nohynek H, Jokinen J, Julkunen I, Kilpi T.

PLoS One. 2014 Dec 15;9(12):e114361. doi: 10.1371/journal.pone.0114361. eCollection 2014.

7.

Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.

Fizazi K, Massard C, Bono P, Jones R, Kataja V, James N, Garcia JA, Protheroe A, Tammela TL, Elliott T, Mattila L, Aspegren J, Vuorela A, Langmuir P, Mustonen M; ARADES study group.

Lancet Oncol. 2014 Aug;15(9):975-85. doi: 10.1016/S1470-2045(14)70240-2. Epub 2014 Jun 25.

PMID:
24974051
8.

No serological evidence of influenza A H1N1pdm09 virus infection as a contributing factor in childhood narcolepsy after Pandemrix vaccination campaign in Finland.

Melén K, Partinen M, Tynell J, Sillanpää M, Himanen SL, Saarenpää-Heikkilä O, Hublin C, Olsen P, Ilonen J, Nohynek H, Syrjänen R, Kilpi T, Vuorela A, Kirjavainen T, Vaarala O, Julkunen I.

PLoS One. 2013 Aug 8;8(8):e68402. doi: 10.1371/journal.pone.0068402. eCollection 2013.

9.

Aging reduces the functionality of anti-pneumococcal antibodies and the killing of Streptococcus pneumoniae by neutrophil phagocytosis.

Simell B, Vuorela A, Ekström N, Palmu A, Reunanen A, Meri S, Käyhty H, Väkeväinen M.

Vaccine. 2011 Feb 24;29(10):1929-34. doi: 10.1016/j.vaccine.2010.12.121. Epub 2011 Jan 12.

PMID:
21236231
10.

Contact sensitization to methylisothiazolinone in Finland--a multicentre study.

Ackermann L, Aalto-Korte K, Alanko K, Hasan T, Jolanki R, Lammintausta K, Lauerma A, Laukkanen A, Liippo J, Riekki R, Vuorela AM, Rantanen T.

Contact Dermatitis. 2011 Jan;64(1):49-53. doi: 10.1111/j.1600-0536.2010.01811.x.

PMID:
21166817
11.

Metabolism of OR-1896, a metabolite of levosimendan, in rats and humans.

Koskinen M, Puttonen J, Pykäläinen M, Vuorela A, Lotta T.

Xenobiotica. 2008 Feb;38(2):156-70. doi: 10.1080/00498250701744658 .

PMID:
18197557
12.

Orally available levosimendan dose-related positive inotropic and lusitropic effect in conscious chronically instrumented normal and heart failure dogs.

Masutani S, Cheng HJ, Hyttilä-Hopponen M, Levijoki J, Heikkilä A, Vuorela A, Little WC, Cheng CP.

J Pharmacol Exp Ther. 2008 Apr;325(1):236-47. doi: 10.1124/jpet.107.134940. Epub 2008 Jan 3.

PMID:
18174383
13.

Efficacy and tolerability of continuous combined hormone replacement therapy in early postmenopausal women.

Mattsson LA, Skouby S, Rees M, Heikkinen J, Kudela M, Stadnicki-Kolendo A, Mattila L, Salminen K, Vuorela A, Mustonen M; Indivina 321 Study Group.

Menopause Int. 2007 Sep;13(3):124-31.

PMID:
17785038
14.

Patch test reactions to cosmetic allergens in 1995-1997 and 2000-2002 in Finland--a multicentre study.

Hasan T, Rantanen T, Alanko K, Harvima RJ, Jolanki R, Kalimo K, Lahti A, Lammintausta K, Lauerma AI, Laukkanen A, Luukkaala T, Riekki R, Turjanmaa K, Varjonen E, Vuorela AM.

Contact Dermatitis. 2005 Jul;53(1):40-5.

PMID:
15982231
15.

High-level production of human type I collagen in the yeast Pichia pastoris.

Nokelainen M, Tu H, Vuorela A, Notbohm H, Kivirikko KI, Myllyharju J.

Yeast. 2001 Jun 30;18(9):797-806.

16.

A multicenter study of patch test reactions with dental screening series.

Kanerva L, Rantanen T, Aalto-Korte K, Estlander T, Hannuksela M, Harvima RJ, Hasan T, Horsmanheimo M, Jolanki R, Kalimo K, Lahti A, Lammintausta K, Lauerma A, Niinimäki A, Turjanmaa K, Vuorela AM.

Am J Contact Dermat. 2001 Jun;12(2):83-7.

PMID:
11381343
17.

Expression of recombinant human type I-III collagens in the yeast pichia pastoris.

Myllyharju J, Nokelainen M, Vuorela A, Kivirikko KI.

Biochem Soc Trans. 2000;28(4):353-7. Review.

PMID:
10961918
19.

Accumulation of properly folded human type III procollagen molecules in specific intracellular membranous compartments in the yeast Pichia pastoris.

Keizer-Gunnink I, Vuorela A, Myllyharju J, Pihlajaniemi T, Kivirikko KI, Veenhuis M.

Matrix Biol. 2000 Feb;19(1):29-36.

PMID:
10686423
20.
21.

Dose dependency of antibody response in infants and children to pneumococcal polysaccharides conjugated to tetanus toxoid.

Ahman H, Käyhty H, Vuorela A, Leroy O, Eskola J.

Vaccine. 1999 Jun 4;17(20-21):2726-32.

PMID:
10418924
22.

MRI of breast hemangioma.

Vuorela AL.

J Comput Assist Tomogr. 1998 Nov-Dec;22(6):1009-10. No abstract available.

PMID:
9843250
23.

Mutacin production by Streptococcus mutans may promote transmission of bacteria from mother to child.

Grönroos L, Saarela M, Mättö J, Tanner-Salo U, Vuorela A, Alaluusua S.

Infect Immun. 1998 Jun;66(6):2595-600.

25.

Pentavalent pneumococcal oligosaccharide conjugate vaccine PncCRM is well-tolerated and able to induce an antibody response in infants.

Ahman H, Käyhty H, Tamminen P, Vuorela A, Malinoski F, Eskola J.

Pediatr Infect Dis J. 1996 Feb;15(2):134-9.

PMID:
8822286
26.
27.

Slowly growing pulmonary metastases of malignant cervical chemodectoma.

Vuorela AL, Jakobsson M, Anttinen J.

Acta Oncol. 1994;33(1):77-8. No abstract available.

PMID:
8142132
28.

Primary chemodectoma of the lung.

Vuorela AL, Anttinen J.

AJR Am J Roentgenol. 1993 Nov;161(5):1111-2. No abstract available.

PMID:
8273623
29.

Preoperative hook-wire localization of nonpalpable breast lesions by use of standard and stereotactic technique.

Vuorela AL, Kettunen S, Punto L.

Anticancer Res. 1993 Sep-Oct;13(5C):1873-5.

PMID:
8267395
30.

Serum cortisol and outcome of ischemic brain infarction.

Murros K, Fogelholm R, Kettunen S, Vuorela AL.

J Neurol Sci. 1993 May;116(1):12-7.

PMID:
8509800
31.

Identification of major metabolites of the catechol-O-methyltransferase inhibitor entacapone in rats and humans.

Wikberg T, Vuorela A, Ottoila P, Taskinen J.

Drug Metab Dispos. 1993 Jan-Feb;21(1):81-92.

PMID:
8095232
32.

Blood glucose, glycosylated haemoglobin, and outcome of ischemic brain infarction.

Murros K, Fogelholm R, Kettunen S, Vuorela AL, Valve J.

J Neurol Sci. 1992 Aug;111(1):59-64.

PMID:
1402998
33.
34.

Diagnosing mammary cancer among an unselected Finnish population. Proposal for practical improvements.

Harju E, Vuorela AL, Krees R, Punto L.

In Vivo. 1991 Jul-Aug;5(4):419-20.

PMID:
1810432
35.

Efficacy of erythromycin acistrate (2'-acetyl erythromycin stearate) and erythromycin stearate in experimental infections in mice.

Männistö PT, Hanhijärvi H, Havas A, Vuorela A, Komulainen H, Rauramaa V.

J Pharmacol Exp Ther. 1989 Sep;250(3):1028-33. Erratum in: J Pharmacol Exp Ther 1989 Dec;251(3):1246-7.

PMID:
2778707
36.

Mammographic and palpation findings in the irradiated spared breast.

Vuorela AL, Harju E, Jakobsson M.

Anticancer Res. 1989 Jul-Aug;9(4):1217-21.

PMID:
2817806
37.

Antibiotic concentration in suction skin blister fluid and saliva after repeated dosage of erythromycin acistrate and erythromycin base.

Tuominen RK, Männistö PT, Solkinen A, Vuorela A, Pohto P, Haataja H.

J Antimicrob Chemother. 1988 Jun;21 Suppl D:57-65.

PMID:
3391876
38.

Absorption of erythromycin acistrate and erythromycin base in the fasting and non-fasting state.

Tuominen RK, Männistö PT, Pohto P, Solkinen A, Vuorela A.

J Antimicrob Chemother. 1988 Jun;21 Suppl D:45-55.

PMID:
3391875
39.

Fate of single oral doses of erythromycin acistrate, erythromycin stearate and pelleted erythromycin base analysed by mass-spectrometry in plasma of healthy human volunteers.

Männistö PT, Taskinen J, Ottoila P, Solkinen A, Vuorela A, Nykänen S.

J Antimicrob Chemother. 1988 Jun;21 Suppl D:33-43.

PMID:
3391874
40.
41.

Preliminary pharmacokinetics of the new antitussive compound vadocaine hydrochloride in animals.

Mäntylä R, Männistö PT, Vuorela A, Nissinen E.

Arzneimittelforschung. 1988 Apr;38(4A):624-7.

PMID:
3395399
42.

The effect of an increased ratio of carbidopa to levodopa on the pharmacokinetics of levodopa.

Kaakkola S, Männistö PT, Nissinen E, Vuorela A, Mäntylä R.

Acta Neurol Scand. 1985 Oct;72(4):385-91.

PMID:
4082903
43.
44.

Impairment of captopril bioavailability by concomitant food and antacid intake.

Mäntylä R, Männistö PT, Vuorela A, Sundberg S, Ottoila P.

Int J Clin Pharmacol Ther Toxicol. 1984 Nov;22(11):626-9.

PMID:
6389377
45.

Pharmacokinetics of graded oral doses of sulindac in man.

Mattila J, Mäntylä R, Vuorela A, Lamminsivu U, Männistö P.

Arzneimittelforschung. 1984;34(2):226-9.

PMID:
6539116

Supplemental Content

Loading ...
Support Center